Jounce's Immunotherapy Recruiting Coup

Cancer immunotherapy start-up Jounce Therapeutics scored a major recruiting coup in naming former Merck SVP Richard Murray as its new CEO. At Merck, Murray was integrally involved in advancing Merck's anti-PD-1 program and in ushering pembrolizumab from the lab through to the acceptance of its Biologics License Application filing in just over three years.